Premenstrual syndrome. Pathogenetic aspects of treatment

• Main Authors: Т. Ф. Татарчук, Н. Ф. Захаренко, I. П. Маноляк
• Format: Article
• Language: English
• Published: Publishing House TRILIST 2018-12-01
• Series: Репродуктивная эндокринология
• Subjects: premenstrual syndrome; micronized progesterone; dysmenorrhea; proginorm
• Online Access: http://reproduct-endo.com/article/view/149310
• ISSN: 2309-4117; 2411-1295

The purpose of the described research was to study the effectiveness of the use of micronized progesterone in the treatment of premenstrual syndrome. 68 women of reproductive age from 18 to 40 years old (mean age 31.2 ± 5.3 years) with premenstrual syndrome of mild and moderate severity were studied. The women were randomized into two groups: the treatment group (n = 35) and the control group (n = 33). The study groups were comparable in age and forms of premenstrual syndrome. Patients of treatment group received therapy with Proginorm OVO, 200 mg per day from 16 to 25 days of the menstrual cycle for three cycles. The drug Proginorm OVO was chosen taking into account its properties, which are similar to the properties of natural endogenous progesterone in the presence of progestogenic, antiestrogenic and light antiandrogenic and aldosterone effects. The women of control group did not receive drugs. To alleviate the condition, for patients of both groups were recommended non-drug measures: optimization of work and rest, balanced nutrition, active lifestyle with moderate physical exertion. Authors concluded that the use of micronized progesterone is appropriate and effective in treating the main manifestations of premenstrual syndrome, especially with regard to pain, changes in behavior and symptoms of fluid retention in the body. In this case, the period of premenstrual syndrome manifestations treatment is advisable to continue up to 6 months, preventing the rapid recovery of symptoms after cessation of therapy.